胃癌中ERCC1、XRCC1表达与奥沙利铂化疗疗效之间的关系

Relationship between the expression of ERCC1,XRCC1 and efficacy of adjuvant oxaliplatin-based chemotherapy in the patients with gastric cancer

目的观察胃癌组织中ERCC1、XRCC1的表达变化,探讨其与奥沙利铂化疗疗效的关系。方法采用免疫组化SP法检测80例胃癌患者术后胃癌组织中ERCC1、XRCC1的表达水平,患者术后全部采用FLO-FOX化疗方案,并采用2χ检验、Log-rank分析和Cox风险模型分析ERCC1、XRCC1在胃癌中的表达及其对奥沙利铂化疗疗效的影响。结果胃癌组织中ERCC1、XRCC1阳性率分别是72.50%(58/80)、45.00%(36/80)。Cox比例风险模型分析显示,胃癌组织中ERCC1表达、XRCC1表达、组织学分型和有无脉管癌栓是影响患者预后的独立因素。结论胃癌组织中的ERCC1、XRCC1表达水平与奥沙利铂化疗疗效有关。

Objective To detect the expression of ERCC1,XRCC1,and to investigate the correlation between the ERCC1,XRCC1 expression with the efficacy of adjuvant oxaliplatin-based chemotherapy in gastric cancer patients.Methods The expression levels of ERCC1 and XRCC1 in cancer tissues of 80 gastric cancer patients were detected by immunohistochemical method after surgery,and all of the patients received adjuvant FLO-FOX chemotherapy.The expression of ERCC1,XRCC1 and its relationship with adjuvant oxaliplatin-based chemotherapy were analysed with chisquare test,Log-rank test and Cox regression model risk.Results ERCC1 and XRCC1 were expressed in gastric cancer tissues with the positive rate of 72.50% and 45.00%,respectively.Cox regression model risk analysis showed that the ERCC1 expression level,XRCC1 expression level,histological type and vessel tumor thrombus were independent prognostic facts in the patients.Conclusion The levels of ERCC1 and XRCC1 in gastric cancer correlate with the efficacy of adjuvant oxaliplatin-based chemotherapy.